---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-032272"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:22:23.158243+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Ensysce Biosciences Q2 2024 net loss $2.0M; PF614-MPAR Phase 1b and OUD candidate PF9001 advance

## Summary
- Net loss attributable to common stockholders was $2.0M in Q2 2024 vs $2.2M in Q2 2023.
- Cash and cash equivalents totaled $1.0M at June 30, 2024, down from $1.1M at year-end 2023.
- R&D expense fell to $0.9M from $1.6M YoY, driven by lower clinical and pre-clinical costs.
- PF614-MPAR Phase 1b study (PF614-MPAR-102) progressing with Quotient Sciences; overdose protection verification planned.
- PF9001 selected as lead OUD candidate in June; supported by NIH/NIDA HEAL award up to $15M.

## SEC filing metadata
- accession: 0001493152-24-032272
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315224032272/0001493152-24-032272-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315224032272/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-032272
- JSON: https://secwatch.observer/filing/0001493152-24-032272.json
- Plain text: https://secwatch.observer/filing/0001493152-24-032272.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.